4.88
+0.2414(+5.20%)
Currency In USD
Address
1330 Avenue of the Americas
Cleveland, NY 10019
United States of America
Phone
646 813 4701
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
136
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Dr. Vishwas Seshadri M.B.A., Ph.D. | President, Chief Executive Officer & Director | 1.47M | 1976 |
| Dr. Brendan M. O'Malley J.D., Ph.D. | Chief Legal Officer | 777,529 | 1969 |
| Mr. Joseph Walter Vazzano CPA | Chief Financial Officer | 889,039 | 1984 |
| Ms. Megan Callan | Vice President & Head of Quality | 0 | N/A |
| Ms. Alison Hardgrove | Chief People Officer | 0 | N/A |
| Dr. Madhav Vasanthavada M.B.A., Ph.D. | Senior Vice President, Chief Commercial Officer & Head of Business Development | 0 | N/A |
| Mr. Carl Denny | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Mr. Brian Kevany Ph.D. | Senior Vice President, Chief Technology Officer & CSO | 0 | N/A |
| Mr. Jon Voss | Vice President & Head of Quality | 0 | 1960 |
| Mr. Gregory Gin | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.